Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks


Personalized Medicine Patent Law Update

In this timely session, top intellectual property attorneys Catherine Polizzi and Michael Shuster provide an update on patent law pertaining to personalized medicine issues. First, they give a brief recap of 35 U.S.C. 101 case law developments followed by a review of the 2014 Interim Guidance on Patent Subject Matter Eligibility under 35, in view of U.S. Supreme Court decisions. They survey recent patent prosecution results from diagnostics companies such as Myriad, Genomic Health, Ariosa, Sequenom and Roche and recap major litigations involving those and other diagnostics players, highlighting practical implications of developing 101 case law. Attendees will gain insight into how to adapt a patent strategy in light of these new developments.


Catherine Polizzi, Ph.D., Partner, Morrison & Foerster LLP

Dr. Polizzi is a Partner at Morrison & Foerster, where she helps emerging and established companies through the challenging process of obtaining patents, providing strategic, effective portfolio counseling and management.  Read Full Bio

Michael Shuster, Ph.D., Partner, Fenwick & West

Dr. Shuster is a partner in Fenwick & West's Intellectual Property Practice and is co-chair of the firm's Life Sciences Group. Dr. Shuster has legal and technical experience representing companies in biotechnology and high technology areas. Read Full Bio

Web Analytics